IL6 and metabolic dysfunction-associated steatotic liver disease: An example is the “Symbiter” probiotic, which reduces liver fat, TNF-α and IL-6 levels and the activity of transaminases in NAFLD patients, and the modulation of the intestinal microflora may be a breakthrough in the treatment of this disease entity [62].